These Analysts Increase Their Forecasts On Synopsys After Strong Q3 Results

Synopsys, Inc. (NASDAQ: SNPS) reported better-than-expected third-quarter financial results.

Synopsys, Inc. (NASDAQ:SNPS) reported better-than-expected third-quarter financial results.

The company reported quarterly earnings of $2.88 per share, which beat the analyst consensus estimate of $2.74. The company reported quarterly sales of $1.49 billion, which beat the analyst consensus estimate of $1.48 billion.

Synopsys estimates full-year revenue growth in a range between 14% and 15%, with earnings per share growth between 24% and 25%.

The company announced that Sassine Ghazi will become CEO effective Jan. 1 and current CEO Aart de Geus will transition to the role of executive chair.

Synopsys shares gained 2% to $436.87 in today’s pre-market trading session.

These analysts made changes to their price targets on Synopsys following earnings announcement.

  • Keybanc raised the price target on Synopsys from $500 to $515. Keybanc analyst Jason Celino maintained an Overweight rating.
  • Baird boosted the price target on Synopsys from $491 to $505. Baird analyst Joe Vruwink maintained an Outperform rating.
  • Rosenblatt raised the price target on Synopsys from $448 to $485. Rosenblatt analyst Blair Abernethy maintained a Buy rating.

Read More: Fear & Greed Index Moves To ‘Neutral’ Zone After Fed Minutes

Total
0
Shares
Related Posts
Read More

GSK Plc Announces The CHMP Of The EMA Has Adopted A Positive Opinion Recommending Approval Of Momelotinib For The Treatment Of Disease-related Splenomegaly Or Symptoms In Adult Patients With Moderate To Severe Anaemia

GSK plc (NYSE: GSK) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of momelotinib for the treatment of disease-related splenomegaly (enlarged spleen) or symptoms in adult patients with moderate to severe anaemia

GSK